Publications by authors named "P Jailwala"

Transfer RNA (tRNA) modifications are crucial for protein synthesis, but their position-specific physiological roles remain poorly understood. Here we investigate the impact of N4-acetylcytidine (acC), a highly conserved tRNA modification, using a Thumpd1 knockout mouse model. We find that loss of Thumpd1-dependent tRNA acetylation leads to reduced levels of tRNA, increased ribosome stalling, and activation of eIF2α phosphorylation.

View Article and Find Full Text PDF

Background: There is no universally accepted treatment for patients with advanced papillary renal cell carcinoma (PRCC). The presence of activating mutations in MET, as well as gain of chromosome 7, where the MET gene is located, are the most common genetic alterations associated with PRCC, leading to the clinical evaluation of MET tyrosine kinase inhibitors (TKIs) in this cancer. However, TKIs targeting MET selectively, as well as multitargeted TKIs with activity against MET demonstrate modest efficacy in PRCC and primary and secondary treatment failure is common; other approaches are urgently needed to improve outcomes in these patients.

View Article and Find Full Text PDF

Advances in gene therapy research have resulted in the successful development of new therapies for clinical use. Here, we explored a gene targeting approach to deplete ephrinB2 from colorectal cancer cells using an inducible lentiviral vector. EphrinB2, a transmembrane ephrin ligand, promotes colorectal cancer cell growth and viability and predicts poor patient survival when expressed at high levels in colorectal cancer tissues.

View Article and Find Full Text PDF
Article Synopsis
  • CAR T-cell therapy can cause a severe side effect known as chimeric antigen receptor-associated hemophagocytic lymphohistiocytosis (carHLH), which is linked to cytokine release syndrome (CRS) in some patients.
  • In a study of 59 patients who received CD22 CAR T cells, about 40% developed carHLH, showing symptoms like high ferritin levels, liver issues, and low white blood cell counts.
  • The development of carHLH is associated with pre-existing low levels of natural killer (NK) cells and higher ratios of T cells to NK cells in the bone marrow, especially after CAR T-cell expansion, indicating a need for better identification and management strategies for this condition
View Article and Find Full Text PDF

Clinical applications of precision oncology require accurate tests that can distinguish true cancer-specific mutations from errors introduced at each step of next-generation sequencing (NGS). To date, no bulk sequencing study has addressed the effects of cross-site reproducibility, nor the biological, technical and computational factors that influence variant identification. Here we report a systematic interrogation of somatic mutations in paired tumor-normal cell lines to identify factors affecting detection reproducibility and accuracy at six different centers.

View Article and Find Full Text PDF